Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.

The plant will be built on Novasep's existing Mourenx site in France and will be operational and validated within 18 months. Both the development of an advanced purification process and the plant expansion within the challenging timescale are results of the sharp increase in the projected demand for a large volume, highly purified API.

The EUR 30 million investment follows two other significant global investments in 2012. The first is the opening of a new 2,000m2 facility in Shanghai, China and the second is a EUR three million investment to expand the Highly Potent API (HPAPI) manufacturing capabilities at the facility in Le Mans, France. 

Novasep has pioneered continuous chromatography for pharmaceutical manufacturing for more than 20 years. Its SMB and Varicol(R) continuous chromatography technologies are currently used for commercial scale production of several chiral APIs. The new plant, designed by a Novasep in-house engineering team, will include Varicol(R) systems with 1,200 mm diameter columns operated at up to 70 bars, the largest ever built in the pharmaceutical industry. The plant will enable the production of a highly purified API from a complex mixture. The systems will also integrate sophisticated solvent recovery systems for the recycling of 99.9 per cent of solvents, resulting in both a very cost-effective and environmentally friendly process.

"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, President and CEO of Novasep. "This successful project, the world's largest chromatography plant in the pharmaceutical industry, demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification. We thank our institutional partners for their active support and our shareholders for their strong involvement to enable this transforming project."

Beyond Novasep's commitment, the EUR 30 million investment has been made possible through financial and/or logistic support by the following partners: the association of local authorities of Lacq, the General Council of Pyrénées Atlantiques, the Regional Council of Aquitaine, the Economic Development Bureau, DIRECCTE Aquitaine, the Prefecture of Pyrénées Atlantiques, the Total Group, and OSEO, France's innovation partner. The plant will leverage the SOBEGI platform's utility supply.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Expands and Opens Subsidiary in India
Subsidiary to meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Friday, February 14, 2014
Novasep Attracts Top Talent to Complete its Executive Team
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Monday, January 20, 2014
Novasep Expands and Opens Subsidiary in India
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Monday, December 16, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos